磺脲类药物基因组学研究进展
摘要
口服降糖药是目前治疗2型糖尿病（T2DM）的方法之一。作为最常用的口服降糖药，磺脲类已在临床应用50余年，它起效快，患者对其耐受性强，但在不同个体间的疗效差异较大。其原因除了不同个体胰岛B细胞功能受损情况、葡萄糖基线水平以及胰岛素抵抗严重程度不同外，患者的遗传背景差异也是造成疗效不同的原因之一。药物基因组学是在药物遗传学基础上发展起来的新兴学科，
出处
《中华糖尿病杂志》
CAS
2012年第12期750-753,共4页
CHINESE JOURNAL OF DIABETES MELLITUS
参考文献31
-
1Marchetti P, Navalesi R. Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents. An update. Clin Pharmacokinet, 1989,16 : 100-128.
-
2Krentz AJ, Bailey CJ. Oral antidiabetic agents: cun'ent role in type 2 diabetes mellitus. Drugs,2005,65:385-411.
-
3Surendiran A, Pradhan SC, Agrawal A, et al. Influence of CYP2C9 gene polymorphisms on response to glibenclamide in type 2 diabetes mellitus patients. Eur J Clin Pharmacol,2011,67 :797- 801.
-
4Kirchheiner J, Bauer S, Meineke I, et al. hnpact of CYP2C9 and CYP2CI9 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics, 2002,12 : 101-109.
-
5Becket ML, Visser LE, Trienekens PH, et al. Cytochrome P450 2C9 * 2 and * 3 polymorphisms and the dose and effect of sulfonylurea in type 2 diabetes mellitus. Clin Pharmacol Ther, 2008,83 : 288-292.
-
6Zhou K, Donnelly L, Burch L, et al. Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes : a Go-DARTS study. Clin Pharmacol Ther,2010,87 : 52- 56.
-
7Holstein A, Plaschke A, Ptak M, et al. Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br J Clin Pharmaco1,2005,60 : 103-106.
-
8Ragia G, Petridis I, Tavridou A, et al. Presence of CYP2C9 * 3 'allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas. Pharmaeogenomics, 2009, 10: 1781- 1787.
-
9van Dam RM, Hoebee B, Seidell JC, et al. Common variants in tbe ATP-sensitive K + channel genes KCNJl1 ( Kit6. 2 ) and ABCC8 (SUR1) in relation to glucose intolerance: population- based studies and meta-analyses. Diabet Med,2005,22:590-598.
-
10Zhang H, Liu X, Kuang H, et al. Association of sulfonylurea receptor 1 genotype with therapeutic response to gliclazide in type 2 diabetes. Diabetes Res Clin Pract,2007,77:58-61.
-
1武晋晓.胰岛素增敏剂应用，贯穿糖尿病发展各阶段[J].糖尿病之友,2010(9):55-55.
-
2李群娜,詹思延.药物不良反应的遗传学基础[J].药物不良反应杂志,2002,4(1):38-42. 被引量：1
-
3肖笛,周宏灏,刘昭前.常用口服降糖药的药物基因组学研究进展[J].中南药学,2013,11(10):745-750.
-
4药物过敏与遗传学的关系[J].经济导报（医药技术）,2009(1):11-11.
-
5张权.酵母——药物遗传学研究的敲门砖[J].国外医学（药学分册）,2006,33(5):396-396.
-
6徐亮.个体化用药中药物反应性的预测[J].国外医学（药学分册）,2006,33(5):394-394.
-
7药物不良反应的遗传学基础[J].国际药学研究杂志,2009,36(4):320-320.
-
8蒋玉洁,齐文雪,蒋升.不同尿酸水平初诊2型糖尿病患者视野受损情况比较及危险因素分析[J].实用糖尿病杂志,2017,13(1):52-54.
-
9张慧娟,刘晓民,苏颖.磺脲类降糖药物的基因组学研究进展[J].中国临床药学杂志,2005,14(3):196-198. 被引量：4
-
10纪建波,张庆柱,李倩,王韦玮.托吡酯对癫痫持续状态大鼠海马神经元损伤的影响[J].山东医药,2006,46(8):23-24. 被引量：1
